Opus Genetics (IRD)
Develops mutation-specific retinal gene therapies alongside partnered and investigational ophthalmology medicines.
$5.12
After-hours close−0.03 (−0.57%)
At close$5.15(−1.34%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Insiders | 11.27% | 9.17M shares | |
|---|---|---|---|
| 15 holders · as of Sep 11, 2026 | |||
| Strategic holders | 4.66% | 3.79M shares | |
| 1 holder · as of May 20, 2026 | |||
| Other | 84.07% | 68.43M shares | |
| remainder | |||
81.40M company shares as of Sep 23, 2026 · holders as of their latest filing
13F
No 13F holders on record.
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Perceptive Advisors LLC | 9.99% | 8.83M | 13G | May 15, 2026 |
| Caligan Partners LP | 8.50% | 6.08M | 13G | May 15, 2026 |
| Adage Capital Management, L.P. | 8.47% | 6.03M | 13G | May 13, 2026 |
| Balyasny Asset Management L.P. | 7.18% | 5.11M | 13G | May 15, 2026 |
| Nantahala Capital Management, LLC | 6.51% | 4.84M | 13G | May 15, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 3, 2026 | Robert E. Gagnonofficer: Chief Financial Officer | Sale | 28,000 | $4.54 | 556,375 |
| Jul 23, 2026 | Robert E. Gagnonofficer: Chief Financial Officer | Sale | 7,783 | $2.95 | 584,375 |
| Jul 23, 2026 | George Magrathdirector, officer: Chief Executive Officer | Sale | 9,475 | $2.95 | 1,731,869 |
| Jul 23, 2026 | Joseph K. Schachleofficer: Chief Operating Officer | Sale | 4,644 | $2.94 | 291,440 |
| Jul 23, 2026 | Benjamin R. Yerxadirector, officer: President | Sale | 7,429 | $2.97 | 704,106 |
| May 18, 2026 | Foundation Fighting Blindness Retinal Degeneration Funddirector, other: See Remarks | Sale | 1,700,000 | $4.35 | 3,792,171 |
| Apr 23, 2026 | Robert E. Gagnonofficer: Chief Financial Officer | Sale | 7,842 | $5.18 | 592,158 |
| Apr 23, 2026 | Ashwath Jayagopalofficer: Chief Scientific & Dev. Ofc. | Sale | 7,542 | $5.19 | 509,233 |
| Apr 23, 2026 | George Magrathdirector, officer: Chief Executive Officer | Sale | 9,511 | $5.22 | 1,741,344 |
| Apr 23, 2026 | Rabourn Amy Zarembaofficer: Head of Fin. Quality Assurance | Sale | 1,641 | $5.20 | 188,671 |
House and Senate disclosures
Not reported.